This review article considers the rising demand for patient-reported outcome measures
(PROMs) in modern ophthalmic research and clinical practice. We review what PROMs are …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Introduction: Conventional immunosuppressive drugs, anti-TNF alpha treatments and
biotherapies are increasingly being used in non-infectious uveitis. Areas covered: The …

Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are
the leading causes of blindness worldwide. The mainstay of treatment for these blinding …

Advanced sarcoidosis : Current Opinion in Pulmonary Medicine Advanced sarcoidosis :
Current Opinion in Pulmonary Medicine Log in or Register Subscribe to journalSubscribe …

Adalimumab, the first fully humanised monoclonal antibody against tumour necrosis factor
alpha (TNF-α), has played a leading role in the revolution brought about by the introduction …

Background/Aim To report the efficacy and tolerability of antitumour necrosis factor-alpha
therapy (TNF inhibitors [TNFi]) in the management of non-infectious ocular inflammation …

Objective To evaluate the demographics, aetiologies, complications, treatments and visual
prognoses of chronic and recurrent non-infectious paediatric-onset uveitis in France …

Objective. This study was aimed at assessing the long‐term ocular control of adalimumab
(ADA) in a large real‐world population with noninfectious primary or secondary uveitis …

Background. Uveitis is a known ophthalmologic manifestation of seronegative
spondyloarthropathy, including psoriatic arthritis. However, the data is less clear among …